(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan- Best Quest for new employment Site for You to Track down Amazing open doors
- Putin critic gets six years in penal colony, vows hunger strike
- Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency
- Picking Childcare Administrations for Your Loved ones
- Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
- Traveling Alone: An Excursion of Self-Disclosure
